Covid-19 roundup: Eu­rope is ‘weeks away’ from remde­sivir de­ci­sion; John Far­ley gets per­ma­nent gig as chief of FDA di­vi­sion steer­ing pan­dem­ic re­sponse

Gilead’s remde­sivir — the first drug shown to ben­e­fit Covid-19 pa­tients in a ran­dom­ized, con­trolled tri­al set­ting — is po­ten­tial­ly a hop, skip and a jump away from se­cur­ing Eu­ro­pean en­dorse­ment for Covid-19.

A rolling ap­pli­ca­tion was kicked off for the ther­a­py in late April, and on Mon­day, the EMA said it ex­pect­ed to pub­lish its opin­ion “with­in weeks.” Pre­vi­ous­ly, the reg­u­la­tor rec­om­mend­ed ex­pand­ing com­pas­sion­ate use of remde­sivir in se­vere Covid-19 pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER